EXTON, PA — Lungpacer Medical has enrolled the first patient in a multicenter study of its FDA-approved AeroPace System, seeking additional evidence of the device’s safety and effectiveness in helping critically ill patients discontinue mechanical ventilation.
The Exton-based medical device company said the AERO-PAS study began at Sutter Health’s California Pacific Medical Center in San Francisco, where Dr. George S. Horng, medical director of critical care services, is serving as principal investigator.
The prospective, single-arm study will enroll up to 120 adults who have required mechanical ventilation for at least 96 hours and have been unable to discontinue ventilator support. Researchers will collect safety and effectiveness data through 30 days of follow-up.
The study follows Lungpacer’s randomized RESCUE-3 pivotal trial, which supported FDA premarket approval of AeroPace.
According to Lungpacer, RESCUE-3 demonstrated 43% faster ventilator weaning and an average reduction of three days in intensive care unit ventilator time per patient.
AeroPace is designed to address ventilator-induced diaphragm dysfunction, a condition in which prolonged mechanical ventilation weakens the diaphragm through inactivity, making it more difficult for patients to resume independent breathing.
The system uses a catheter inserted into a central vein to stimulate the phrenic nerves, triggering diaphragm contractions intended to maintain or improve respiratory muscle function.
“Patients who fail to wean after several days on the ventilator are some of the most challenging we care for, and every additional ventilator day adds risk for the patient and strain on the ICU,” Horng said.
The post-approval study will assess how the treatment performs in routine clinical settings, extending the evidence collected during the controlled pivotal trial.
The findings could help hospitals and insurers evaluate the treatment’s role in managing patients who require prolonged mechanical ventilation, a population associated with substantial intensive care resource use.
Doug Evans, Lungpacer’s president and chief executive officer, said the study will examine whether the benefits observed in RESCUE-3 translate into everyday hospital practice.
Additional clinical sites are expected to begin participating in the coming months, with enrollment scheduled for completion in 2028.
The study is registered on ClinicalTrials.gov under identifier NCT07477054.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
